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Lille, Lille, FranceAbstractPneumocystis colonization may play a role in transmission and local
inﬂammatory response. It was explored in patients with respiratory
diseases in North Lebanon. Overall prevalence reached only 5.2%
(95% CI 2.13–10.47) but it was higher (17.3%) in the
subpopulation of patients with chronic obstructive pulmonary
disease (COPD). COPD was the only factor associated with a
signiﬁcantly increased risk of colonization. mtLSU genotyping
revealed predominance of genotype 2, identiﬁed in ﬁve patients
(71.4%), including one patient who had co-infection with
genotype 3. These ﬁrst data in North Lebanon conﬁrm
Pneumocystis circulation among patients with respiratory diseases
and the potential for transmission to immunocompromised
patients.
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E-mail: emilie.frealle@pasteur-lille.frPneumocystis colonization occurs in both immunocompetent
and immunocompromised individuals, reaching 0–65% in the
general population [1,2], 20–69% in human immunodeﬁciency
virus (HIV) – infected patients [3] and 16–55% in patients with
chronic obstructive pulmonary disease (COPD) [1,3,4]. Colo-
nized individuals may be at risk of developing Pneumocystis
pneumonia (PcP) or serve as a reservoir for transmission [3].
Moreover, Pneumocystis may stimulate the host inﬂammatory
response, lead to lung damage and play a role in the progression
of lung diseases such as COPD [3].
In this study, which was approved by institutional review
boards of the Lebanese university and of the different hospitals,
Pneumocystis colonization was prospectively explored in 134
patients with community-acquired respiratory diseases (33
rhinopharyngitis, 27 bronchitis, 23 COPD, 17 inﬂuenza, 14
asthma, eight respiratory infections, four pneumonia, four
respiratory distress syndromes, two lung cancers, one ﬁbrosis,
one acute pulmonary oedema). Exclusion criteria were
hospital-acquired respiratory infection and anti-Pneumocystis
jirovecii treatment (with sulfamethoxazole or atovaquone) in the
preceding 6 months. Patients were enrolled from July 2012 to
October 2013 in four hospitals of Tripoli (Tripoli governmental
(n = 13), Nini (n = 69), al Mazloum (n = 14), and el Monla
(n = 12) hospitals) and in local medical care centres (n = 26).
Among hospitalized patients, 92 were recruited during their
stay in Pneumology departments and 16 were recruited from
Oncology-Haematology departments. Standardized forms were
ﬁlled with clinical, biological and demographic data for each
patient: age, sex, presence of chronic pulmonary disease or
other respiratory disease, immune deﬁciencies (cancer, HIV),
corticotherapy and any other immunosuppressive medications,
or antibiotherapy and smoking habits were recorded. Collected
samples (one per patient) included 56 oropharyngeal washes,
37 sputa, 15 tracheal aspirations, 14 bronchoalveolar lavages
and 12 nasal swabs. DNA extraction was performed using the
Nucleospin tissue Kit (Macherey-Nagel, Hoerdt, France).
Pneumocystis DNA was detected using an mtLSU nested-PCR
assay [5]. Positive samples were sequenced and further pro-
cessed to determine fungal load using a quantitative mtLSU PCR
assay [6]. Pneumocystis jirovecii mtLSU sequences were depositedNew Microbe and New Infect 2015; 6: 11–14
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Nested-PCR assay was positive in seven specimens from
patients with COPD (n = 4), rhinopharyngitis (n = 1), bronchitis
(n = 1) and inﬂuenza (n = 1) (Table 1). Prevalence of Pneumo-
cystis colonization reached 5.2% (95% CI 2.13–10.47), which
was within the same range as immunocompetent patients with
various lung diseases in Iran (7.3%), a neighbouring country [7].
The mtLSU quantitative PCR conﬁrmed Pneumocystis DNA
detection for six out of seven samples, with a 7.97 to 3.51 × 104
copies/μL fungal burden (Table 1), which was consistent with
previously reported loads in colonized patients and with the
2 × 104 upper cut-off value that was proposed by Damiani et al.
for differentiation of colonized patients and patients with PcP
[8]. The prevalence was similar in patients with rhinopharyngitis
(3.0%), bronchitis (3.7%), and inﬂuenza (5.9%), but it was higher
in patients with COPD (17.3%, Table 1), conﬁrming previous
data in this population [1,3,4] and potential occurrence of
Pneumocystis in patients with inﬂuenza [9]. Pneumocystis was not
detected in patients with asthma, supporting a lower risk for
colonization in these patients, despite previous reports of an
association between PcP and asthma [10]. No lung cancer pa-
tient was colonized, but only two such patients were included.
This low number of cancer patients, the absence of patients
with cystic ﬁbrosis or interstitial lung diseases, and the high
number of patients with rhinopharyngitis, asthma or inﬂuenza,
could explain our lower overall prevalence when compared
with previous studies in Spain (27.1% in patients with lung
cancer, cystic ﬁbrosis, interstitial lung disease or COPD) [11],
or in the UK (18% in patients with mainly lung cancer or
pneumonia) [12]. As these studies used a nested-PCR assay
without real-time PCR conﬁrmation, an additional explanation
for higher Pneumocystis colonization could be false-positive re-
sults due to carryover contamination. As the prevalence of PcPTABLE 1. Characteristics of patient with Pneumocystis jirovecii carr
PCR and mtLSU genotyping results
Patient
identiﬁcation Localization
Date of
sample
collection Age Sex
Sample
type
Underlying
respirator
disease or
infection
O3 Nini hospital 11/07/13 57 M Sputum COPD SI
X3 Nini hospital 04/06/13 78 M Nasal swab COPD SIII
33 Nini hospital 30/10/12 75 F OPW COPD SIII
V1 Monla hospital 12/09/13 75 M Sputum COPD SIII
P3 Mazloum hospital 25/08/13 70 M BAL Flu
47 Local medical care
centre
01/03/13 53 M OPW Rhino-phary
41 Tripoli
Governmental
hospital
16/11/12 75 M OPW Acute bron
Abbreviations: BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease;
oropharyngeal wash.
aOther risk factors: cancer, immune deﬁciency, corticotherapy, immunosuppressive treatme
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lower prevalence of Pneumocystis colonization in Lebanon could
further be explained by a lower overall burden of Pneumocystis
that could result from the inﬂuence of climatic factors [14].
Finally, differences in genetic susceptibility have been recently
suggested in the Netherlands, where a signiﬁcant lower inci-
dence of PcP was found among HIV-positive Africans compared
with Western patients [15]. Hence, the role of genetic factors
would be interesting to explore in Lebanese patients.
When potential risk factors and sample types were analysed
(Table 2), the frequencies were similar or lower in colonized
patients for all the examined criteria, except sex ratio and
COPD. As the low number of colonized patients induced a high
risk of falsely supported null hypothesis, statistical analyses
were only performed for these criteria. Fisher Exact test
revealed a signiﬁcantly higher prevalence of Pneumocystis colo-
nization in patients with COPD (p 0.019). The higher propor-
tion of males in the Pneumocystis-positive group was not
statistically signiﬁcant (p 0.238), but this result could be due to a
lack of statistical power and should be interpreted carefully.
Nevertheless, Pneumocystis association with COPD conﬁrmed a
previous multivariate analysis that identiﬁed COPD as the only
important predictive factor of colonization [16], but were in
contrast to another study [12]. However, this last study
included only subjects with very mild airway obstruction. Our
study also agreed with this previous study, which did not
identify immunosuppressive treatment and cancer as risk fac-
tors for Pneumocystis colonization [12]. Despite previous re-
ports of association between corticotherapy and Pneumocystis
colonization [12], this criteria did not appear as a risk factor in
our study. This result, which supports data from Morris et al.
[16], could be related to the low number of Lebanese patients
undergoing corticotherapy in our study. Another speciﬁc
feature of our population was the high frequency of smokers oriage: epidemiological, biological and clinical data; quantitative
y
Smoking
habits
Other
risk
factorsa
Microbiological
ﬁndings
P. jirovecii
DNA loads
(copies/μL)
mtLSU
genotype
Yes No Neg 7.97 × 100 Mixture
(2 & 3)
Yes No Neg 3.95 × 101 2
Yes No NA 4.47 × 103 1
Yes No NA 9.71 × 100
NA No Neg Neg 2
ngitis Yes No Neg 5.37 × 102 1
chitis Passive No NA 3.51 × 104 2
mtLSUrRNA, mitochondrial large subunit ribosomal RNA; NA, not available; OPW,
nt, antibiotherapy.
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TABLE 2. Comparison of patient localization, underlying
respiratory diseases, other potential risk factors, and sample
type between Pneumocystis jirovecii colonized and non-
colonized patients
P. jirovecii DNA P. jirovecii DNA
detected
(n [ 7)
not detected
(n [ 127)
Mean age 69.0 ± 9.9 51.0 ± 20.9
Sex ratio 6 1.3
Localization Tripoli Governmental
hospital
1 (14.3%) 12 (9.4%)
Nini hospital 3 (42.8%) 66 (52.0%)
Monla hospital 1 (14.3%) 11 (8.7%)
Mazloum hospital 1 (14.3%) 13 (10.2%)
Local medical care 1 (14.3%) 25 (19.7%)
Population
characteristics
COPDa 4 (57.1%) 19 (14.9%)
Acute bronchitis 1 (14.3%) 26 (20.5%)
Pulmonary ﬁbrosis 0 (0%) 1 (0.8%)
Inﬂuenza 1 (14.3%) 16 (12.6%)
Rhinopharyngitis 1 (14.3%) 32 (25.2%)
Asthma 0 (0%) 14 (11.0%)
Pneumonia 0 (0%) 4 (3.1%)
Respiratory infection 0 (0%) 8 (6.3%)
Acute pulmonary
oedema
0 (0%) 1 (0.8%)
Respiratory distress
syndrome
0 (0%) 4 (3.1%)
Lung cancer 0 (0%) 2 (1.6%)
Other risk factors Cancer 0 (0%) 16 (12.6%)
Immune deﬁciency 0 (0%) 1 (0.8%)
Corticotherapy 0 (0%) 5 (3.9%)
Immunosuppressive
treatment
0 (0%) 16 (12.6%)
Antibiotherapy 0 (0%) 10 (7.9%)
Type of samples OPW 3 (42.8%) 53 (41.7%)
Sputum 2 (28.6%) 35 (27.5%)
BAL 1 (14.3%) 13 (10.8%)
Nasal swab 1 (14.3%) 11 (8.7%)
Tracheal aspiration 0 (0%) 15 (11.8%)
Abbreviations: BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary
disease; OPW, oropharyngeal wash.
aBecause the number of colonized patients was low, the statistical analyses were not
performed for criteria with similar or lower frequencies in colonized and non-
colonized patients. Among the risk factors tested (i.e. sex ratio and COPD), COPD
was the only one associated with a signiﬁcant increased risk of Pneumocystis
colonization (p 0.019).
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dividuals (100% and 81.5% in six colonized and 65 non-
colonized individuals for whom smoking habit was successfully
determined, respectively). This result supported previous data
reporting that smoking is not a risk factor for Pneumocystis
colonization [16]. Lastly, the similar frequency of positivity of
bronchoalveolar lavages, sputa, oropharyngeal washes and nasal
swabs (Table 2) conﬁrmed the usefulness of non-invasive
samples, especially nasal swabs, which are not usually used for
Pneumocystis detection [17].
The mtLSU genotyping revealed predominance of genotype 2
(85A; 248C) (71.4%). One patient had co-infection with geno-
type 3 (85T; 248C). Genotype 1 (85C; 248C) was found in two
patients (Table 1). The very low number of samples in which
Pneumocystis colonization was detected limits comparison with
other studies. However, it should be noted that genotype 2 was
also found to be predominant in Italy (39%) [18] and in Cuba
(48%) [19]. Nevertheless, our results contrasted with a Spanish
study that reported a predominance of genotype 1 in patientsNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artiwith pulmonary diseases (45%) [11]. Seasonal variation in the
occurrence of Pneumocystis genotypes, which has been reported
in the UK [20], was suggested by identiﬁcation of most genotype
2 isolates during the dry season (June–September) whereas both
patients with genotype 1 isolates were sampled during the wet
season (March–October) (Table 1).
To our knowledge, this is the ﬁrst investigation of Pneumo-
cystis carriage in Lebanon. These ﬁrst data from North Lebanon
conﬁrm colonization of patients with respiratory diseases,
which may evolve into PcP if the underlying disease reaches a
severe stage or in the absence of appropriate treatments.
Furthermore, the circulation of P. jirovecii among patients with
respiratory diseases indicates its potential for transmission to
immunocompromised patients.
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